Two-Part Ebola Vaccine Regimen may Offer Protection for a Year

The two-vaccine regimen is safe, well-tolerated and induced immune responses in participants eight months after immunization.

A two-part Ebola vaccine regimen has been found to offer protection against the deadly disease for about a year in an early human trial.

The vaccine regimen induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from the phase-1 clinical trial published in the Journal of the American Medical Association.

Russia Says Its Ebola Vaccine Shows Encouraging Results in Initial Tests
Russia's health minister revealed that an Ebola vaccine developed by the country over the last 15 months had shown encouraging results.

‘The two-part Ebola vaccine was safe and well-tolerated in the participants after immunization. Additional research is necessary to assess the durability of immunity beyond one year.’

The experimental vaccines included Ad26.ZEBOV, developed by Johnson & Johnson, and MVA-BN-Filo, developed by Denmark-based Bavarian Nordic.

Both of the vaccines in the regimen use harmless viral vectors, or carriers, to deliver proteins of the Ebola virus, which prompt an immune response.

The trial, conducted by Matthew D. Snape of the University of Oxford and colleagues, enrolled healthy participants aged 18-50 years in Britain.

Inner Workings of Ebola Vaccine Trial To Be Presented
Ring vaccination was first used in the 1970s to eradicate smallpox. Researchers expect the vaccination strategy could be used to combat other emerging pathogens.

Participants were selected randomly to receive either the two-vaccine regimen or placebo (saltwater injections).

Previously reported initial results showed the two-vaccine regimen is safe, well-tolerated and induced immune responses in participants eight months after immunisation.

Charity Buys Experimental Ebola Vaccine From Merck
To thwart any return of the deadly ebola epidemic, Charity alliance Gavi committed to buy $5 million worth of an experimental Ebola vaccine from drugmaker Merck.

Of the 75 participants who received the vaccine regimen, 64 remained in the study for a follow-up visit on day 360.

No serious vaccine-associated adverse events were observed, and all 64 participants maintained antibodies to Ebola virus at day 360.

China's Tianjin CanSino Biotechnology Inc. to Mass Produce Ebola Vaccine
Developed by a team of Chinese scientists the Ebola vaccine is based on the 2014 mutant gene type and in the form of freeze-dried powder.

The researchers noted that additional research is necessary to assess the durability of immunity beyond one year and the immune response to booster doses of vaccine.

Source-IANS